Lipoprotein(a), pronounced "L-P-little-a," is an LDL-like particle with an extra protein called apolipoprotein(a) attached. Its level is ~90% genetically determined and typically stable across a lifetime, meaning one test can settle the question for most adults.
Elevated Lp(a) is an independent cardiovascular risk factor that operates beyond standard cholesterol markers. It promotes atherosclerosis, thrombosis, and aortic valve calcification. Roughly 20% of the population has meaningfully elevated levels, and the marker is underordered in standard clinical practice. Testing once in adulthood is enough for most people, and a normal result removes this as an ongoing concern.
Optimal Lipoprotein (a): 0-14 mg/dL.
Typically re-tested every 52 weeks.
Unlike most of a standard lipid panel, it moves very little with day to day eating or training, so a single measurement usually describes you well. This page is educational and not medical advice.
Lipoprotein (a) is a low-density lipoprotein particle that carries a second protein, apolipoprotein(a), attached to the apolipoprotein B-100 on its surface 1.
Every LDL particle has one apolipoprotein B-100 molecule holding it together. In Lp(a), a glycoprotein called apo(a) is bound to that shell by a disulfide bond, which turns an ordinary LDL-like particle into something structurally different. Apo(a) is built from repeated loop-shaped domains known as kringles, and it is strikingly similar in structure to plasminogen, the precursor of the enzyme that breaks down fibrin clots 3.
The number of one particular repeat, kringle IV type 2, varies widely between people and is inversely related to how much Lp(a) circulates. Fewer repeats generally mean a higher blood concentration 3. That variation is written into the LPA gene, which is why levels are largely fixed from early life rather than earned or lost through lifestyle. The particle is made in the liver, and research on exactly how it is assembled and cleared from circulation is still incomplete 2.
One practical detail matters before you read any result. Laboratories report Lp(a) either as a mass in mg/dL or as a particle concentration in nmol/L, and the two are not interchangeable by a simple conversion factor, because particles differ in size between individuals 7. Always check which unit your report uses.
Related: Does Lipoprotein (a) Need to Be Fasting? (Test Prep)
It matters because the cardiovascular risk associated with Lp(a) appears to run largely independently of LDL cholesterol, so a reassuring LDL result does not necessarily account for it. A participant-level meta-analysis found that Lp(a)-associated risk and LDL cholesterol-associated risk behave as separate contributions rather than one standing in for the other 4.
Three mechanisms are usually described. The particle delivers cholesterol into the arterial wall much as LDL does. It also carries oxidized phospholipids, which research associates with inflammation in the vessel wall and in heart valve tissue 1. And because apo(a) resembles plasminogen, there is a long-standing hypothesis that it may interfere with clot breakdown, although this remains an area of active investigation rather than settled fact 3.
Beyond the coronary arteries, a systematic review and meta-analysis associated higher Lp(a) with faster progression of calcific aortic valve stenosis, the gradual stiffening and narrowing of the aortic valve 5. That link is one reason Lp(a) is discussed separately from the rest of a lipid panel.
The risk signal also persists in people already taking lipid-lowering medication. An individual patient-data meta-analysis of statin outcome trials reported that both baseline and on-statin Lp(a) levels predicted cardiovascular events 6. Reviews of lipid testing describe measuring Lp(a) at least once in adult life, on the reasoning that the value rarely shifts much and a single result informs risk conversations for decades 7.
Most laboratories regard a mass-based result below roughly 30 mg/dL as within the typical reference range, while FitScript sets a tighter optimization target.
| Measure | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Lipoprotein (a), mass assay (mg/dL) | 0 to 30 mg/dL | 0 to 14 mg/dL |
Reference ranges vary by laboratory, assay, age and sex, so read your own report's stated range first. FitScript's optimal range is an optimization target, not a diagnostic cut-off, and a value outside it is a prompt for a conversation rather than a conclusion about your health. No separate ranges by age or by sex are published here, because none are supplied for this marker.
Two caveats make the number harder to read than it looks. First, results reported in nmol/L cannot be mapped onto a mg/dL threshold with a fixed multiplier, so comparing results from two different assays can mislead 7. Second, the distribution of Lp(a) differs substantially across ethnic groups, which means a single universal threshold does not carry identical meaning for everyone 8. Interpretation works best alongside family history and the rest of your lipid and inflammatory markers.
A high Lp(a) result means you carry more of this particle than most people, which research associates with greater long-term cardiovascular risk 1. It does not mean you have heart disease, and it cannot be read as a diagnosis on its own.
What people notice. Usually nothing. Lp(a) produces no symptoms of its own, and people are almost always unaware of their level until it is measured. Symptoms that sometimes bring the marker to attention belong to downstream conditions rather than to the number itself. In people with significant coronary narrowing, that can mean chest tightness or breathlessness on exertion; in people with aortic valve narrowing, reduced exercise tolerance, breathlessness or lightheadedness. Those symptoms warrant prompt medical attention regardless of any lab value.
Common causes. Genetics dominates. Variation in the LPA gene, particularly the kringle IV type 2 repeat number, explains most of the between-person difference 3, and average levels differ across ethnic groups 8. Non-genetic influences are smaller but real. Reduced kidney function and nephrotic syndrome are associated with higher measured levels 11, levels tend to be modestly higher after menopause, and acute inflammation or illness can raise a reading temporarily. Statin therapy is also associated with a modest increase in Lp(a) rather than a decrease 9.
Long-term impact. Studies indicate that higher lifetime exposure to Lp(a) is associated with atherosclerotic cardiovascular events independently of LDL cholesterol 4 and with faster progression of calcific aortic valve stenosis 5. A result well above the standard reference range is suboptimal rather than a verdict, and it is worth discussing with a clinician promptly when it sits alongside a family history of early heart disease, existing cardiovascular disease or other markers outside range.
A low Lp(a) result means this particular particle contributes little to your cardiovascular risk picture. It is generally regarded as a favourable finding.
What people notice. Nothing. There is no recognized symptom pattern attached to low Lp(a), and no deficiency state that the marker is used to detect. Laboratories regard results at the bottom of the range as unremarkable.
Common causes. Again, mostly inheritance. A larger number of kringle IV type 2 repeats in the LPA gene is associated with lower circulating levels 3. Because the particle is produced in the liver, significant liver disease can reduce production and therefore the measured value 10.
Long-term impact. A low value removes one risk contributor, not all of them. The same meta-analysis that separated Lp(a) risk from LDL cholesterol risk also underlines the reverse point, that LDL cholesterol and apolipoprotein B continue to carry risk of their own 4. Whether naturally very low Lp(a) relates to any other outcome is not settled, and there is no established reason to treat a low value as a problem to be corrected.
Less than most people expect, which is precisely what makes the marker useful.
Testing conditions. Fasting is not generally required for lipid testing, and Lp(a) is among the less variable lipid measures 7. Assay choice matters more than timing. Results in mg/dL and nmol/L are not directly comparable, and different assays handle apo(a) size variation differently, so a repeat test is most informative when run on the same assay as the first. Acute infection, recent surgery, significant inflammation and pregnancy can all shift a reading temporarily, so a value drawn during illness is worth repeating once you are well.
Medications. Statins are associated with a small increase in Lp(a) rather than a reduction, a finding reported in a dedicated analysis 9 and consistent with the statin trial meta-analysis showing Lp(a) still predicting events during therapy 6. That is not a reason to stop or change a prescription, which only the prescribing clinician can judge. Some other prescription therapies and lipoprotein apheresis are associated with lower Lp(a), and newer therapies aimed at apo(a) production are still being tested, with outcome data awaited. None of these are described here with doses, schedules or administration steps, and a licensed provider evaluates whether any prescription option is appropriate for an individual.
Habits. Diet, training and body composition shift Lp(a) far less than they shift triglycerides or LDL cholesterol, and the particle appears largely resistant to lifestyle change. The practical use of a high result is usually to raise the priority of everything else that is modifiable, including LDL cholesterol, apolipoprotein B, blood pressure, inflammation and smoking status. A separate FitScript guide covers what influences this marker in more depth.
Lp(a) is measured from a standard venous blood draw as part of cardiovascular lipid testing, and it sits within the heart-focused panel linked below. A FitScript membership includes 150+ biomarkers tested per year, so the result arrives next to the rest of the lipid, metabolic and inflammatory picture rather than on its own.
Atlas, FitScript's AI health advisor, reads the value in context. That means comparing it against both the typical laboratory reference range and the optimal range above, cross-referencing apolipoprotein B and LDL cholesterol to see how much total atherogenic particle burden is present, and flagging patterns worth raising with a clinician. The personalized output Atlas writes from your biology is your FitScript.
Retesting logic differs from most markers. Because the value is genetically anchored and stable, repeat measurement is less about tracking progress and more about confirming an unexpected result on the same assay, or rechecking after a meaningful change in health status such as altered kidney function. Where a result prompts consideration of medication, a licensed provider reviews the full picture and decides whether any treatment option is appropriate. Nothing on this page replaces that evaluation.
Lp(a) is one input into a risk picture that no single number describes. These related markers add the context that makes a result interpretable, and each has its own guide.
All of these are measured together in the Heart Health panel, which is where Lp(a) is most useful, read as one line in a complete cardiovascular picture.
Lipoprotein (a) is an LDL-like particle carrying an extra protein, apo(a), with blood levels set mostly by the LPA gene and largely stable across life. Typical laboratory reference ranges run to about 30 mg/dL, while FitScript's optimal range is 0 to 14 mg/dL. A high result is suboptimal rather than diagnostic, and it is associated in research with atherosclerotic cardiovascular events and with aortic valve stenosis progression 1 5. A low result is reassuring for this one pathway and says nothing about the others. Because the value barely moves with lifestyle, its real value is in sharpening how closely everything else gets managed. Discuss your results, and any treatment question they raise, with a clinician or licensed provider.
No. Lp(a) is an LDL-like particle with an additional protein, apolipoprotein(a), bound to its surface. The cardiovascular risk associated with Lp(a) runs largely independently of LDL cholesterol, which is why a normal LDL result does not account for it and why the two are reported separately.
Most laboratories regard mass-based results above roughly 30 mg/dL as outside the typical reference range, while FitScript's optimal range is 0 to 14 mg/dL. Ranges vary by laboratory and assay, and results reported in nmol/L cannot be converted to mg/dL with a fixed factor, so read your own report's stated range.
Fasting is not generally required for lipid testing, and Lp(a) is among the more stable lipid measures. Acute illness, infection, recent surgery or pregnancy can shift a reading temporarily, so a result drawn while unwell is worth repeating once you have recovered. Follow whatever instructions your testing provider gives.
Because the value is largely genetically determined and stable across life, reviews of lipid testing describe measuring it at least once in adulthood. Repeat testing is usually about confirming an unexpected result on the same assay, or rechecking after a meaningful change in health status. Your clinician decides what makes sense for you.
Lp(a) appears to respond far less to diet, training and weight change than triglycerides or LDL cholesterol do. The practical response to a high result is usually to tighten everything else that is modifiable, including LDL cholesterol, apolipoprotein B, blood pressure, inflammation and smoking status, with a clinician guiding priorities.
No. A single biomarker cannot diagnose a condition. A result above the standard range is suboptimal and indicates greater long-term risk across populations, not a present diagnosis. It is worth discussing with a clinician promptly, particularly alongside a family history of early cardiovascular disease.
The distribution of Lp(a) differs substantially across ethnic groups, so one universal threshold does not carry identical meaning for everyone. Interpretation works best when the value is read alongside family history, apolipoprotein B, LDL cholesterol and inflammatory markers rather than against a single cut-off.
Low readings are generally regarded as favourable from a cardiovascular standpoint, and there is no recognized symptom pattern or deficiency state attached to them. A low value removes one risk contributor, not all of them, so LDL cholesterol and apolipoprotein B still matter. This information is educational, not medical advice.